Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis

Article information

J Bone Metab. 2022;29(4):279-279

Publication date (electronic) : 2022 November 30

doi : https://doi.org/10.11005/jbm.2022.29.4.279

Chaiho Jeong ¹, Jinyoung Kim ², Yejee Lim ³, Jeonghoon Ha ⁴, Moo Il Kang ⁴, Ki-Hyun Baek ²

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

²Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

³Division of General Internal Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, Korea

⁴Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

See the letter "Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis" on page 317.

Journal of Bone Metabolism 2021;28(4):317–323.

Figure 1 should be corrected as follows.

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.